373 related articles for article (PubMed ID: 11248083)
1. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.
Praticò D; Tillmann C; Zhang ZB; Li H; FitzGerald GA
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3358-63. PubMed ID: 11248083
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.
Belton O; Byrne D; Kearney D; Leahy A; Fitzgerald DJ
Circulation; 2000 Aug; 102(8):840-5. PubMed ID: 10952950
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
[TBL] [Abstract][Full Text] [Related]
4. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
McAdam BF; Catella-Lawson F; Mardini IA; Kapoor S; Lawson JA; FitzGerald GA
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):272-7. PubMed ID: 9874808
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice.
Burleigh ME; Babaev VR; Oates JA; Harris RC; Gautam S; Riendeau D; Marnett LJ; Morrow JD; Fazio S; Linton MF
Circulation; 2002 Apr; 105(15):1816-23. PubMed ID: 11956125
[TBL] [Abstract][Full Text] [Related]
7. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
Catella-Lawson F; McAdam B; Morrison BW; Kapoor S; Kujubu D; Antes L; Lasseter KC; Quan H; Gertz BJ; FitzGerald GA
J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture.
Bishop-Bailey D; Larkin SW; Warner TD; Chen G; Mitchell JA
Br J Pharmacol; 1997 May; 121(1):125-33. PubMed ID: 9146896
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo.
Dowd NP; Scully M; Adderley SR; Cunningham AJ; Fitzgerald DJ
J Clin Invest; 2001 Aug; 108(4):585-90. PubMed ID: 11518732
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.
Belton OA; Duffy A; Toomey S; Fitzgerald DJ
Circulation; 2003 Dec; 108(24):3017-23. PubMed ID: 14638539
[TBL] [Abstract][Full Text] [Related]
11. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
12. Selective cyclooxygenase-2 inhibition by nimesulide in man.
Cullen L; Kelly L; Connor SO; Fitzgerald DJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):578-82. PubMed ID: 9808683
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview.
Famaey JP
Inflamm Res; 1997 Nov; 46(11):437-46. PubMed ID: 9427063
[TBL] [Abstract][Full Text] [Related]
15. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.
Nüsing RM; Reinalter SC; Peters M; Kömhoff M; Seyberth HW
Clin Pharmacol Ther; 2001 Oct; 70(4):384-90. PubMed ID: 11673754
[TBL] [Abstract][Full Text] [Related]
16. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y
Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076
[TBL] [Abstract][Full Text] [Related]
17. Generation of 8-epi-prostaglandin F(2alpha) in isolated rat kidney glomeruli by a radical-independent mechanism.
Klein T; Neuhaus K; Reutter F; Nüsing RM
Br J Pharmacol; 2001 Jul; 133(5):643-50. PubMed ID: 11429387
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.
Giuliano F; Warner TD
Br J Pharmacol; 1999 Apr; 126(8):1824-30. PubMed ID: 10372826
[TBL] [Abstract][Full Text] [Related]
19. COX-2-derived prostacyclin confers atheroprotection on female mice.
Egan KM; Lawson JA; Fries S; Koller B; Rader DJ; Smyth EM; Fitzgerald GA
Science; 2004 Dec; 306(5703):1954-7. PubMed ID: 15550624
[TBL] [Abstract][Full Text] [Related]
20. Human fallopian tubes express prostacyclin (PGI) synthase and cyclooxygenases and synthesize abundant PGI.
Huang JC; Arbab F; Tumbusch KJ; Goldsby JS; Matijevic-Aleksic N; Wu KK
J Clin Endocrinol Metab; 2002 Sep; 87(9):4361-8. PubMed ID: 12213900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
